Can Milk Help Prevent Transplant Rejections?

Dec 05, 2008
milk

(PhysOrg.com) -- Could Wisconsin's signature product – milk – hold the key to one of the biggest problems in organ transplantation?

Dr. Hans Sollinger, the surgeon who heads the transplant program at UW Hospital and Clinics, is betting on it.

Sollinger recently received FDA approval for a clinical trial testing whether the milk of genetically engineered cows can prevent the rejection of transplanted kidneys.

Each year, thousands of kidney transplants fail because of antibody-mediated rejection (AMR), a phenomenon in which a patient's immune system triggers the production of antibodies that in turn activate a protein called human C1. The protein attacks the transplanted kidney, a process that often leads to the body rejecting the organ

But C1 inhibitor may be able to disrupt the chain reaction that causes AMR. Cows can be genetically engineered to produce milk teeming with the inhibitor.

In the clinical trial, surgeons will identify patients with AMR following a kidney transplant. Half of the trial group will receive the current standard treatment - a blood-cleansing procedure called plasmapheresis - while the other half will receive both plasmapheresis and a course of recombinant C1 from cows' milk.

"A transplant typically rejects one of two ways - either by immune cells or by antibodies," explains Sollinger. "We can combat the immune-cell reaction with cyclosporin and other immunosuppressant agents. Where we are not good is combating antibodies. There's nothing we can do except for washing the antibodies out of the blood, but it's a very time-consuming and expensive process, and most of the time the effects are very short-lasting."

Sollinger's hopes for success are bolstered by medical precedent. Boosting the levels of human C1 inhibitor has been shown in clinical trials to combat a rare disease called hereditary angioedema, a condition in which antibodies trigger swelling and lesions of the skin and mucous membranes.

The trial builds on the work of Dr. Paul Terasaki, the famous transplant surgeon who championed the theory that antibodies, not immune cells, hold the key to preventing organ rejection.

"Dr. Terasaki showed us that in the long term, the grafts that are failing are failing because of antibodies," says Sollinger. "They're a huge problem, and now, for the first time, we have an agent to address it."

The trial is sponsored by and will be conducted in conjunction with Pharming, a European-based biotech company. Sollinger hopes to have results in as little as a year.

"That's why this trial is so exciting," he says. "This is not one of these drugs where we'll have to wait for years to see if it works. We'll know right away."

The transplant program at UW Hospital and Clinics is one of the world's foremost transplant programs, encompassing heart, lung, kidney, pancreas, intestine, islet cell and pediatric transplants. UW Health surgeons and physicians are recognized as experts and pioneers in new surgical techniques.

Provided by University of Wisconsin

Explore further: Mutant protein in muscle linked to neuromuscular disorder

add to favorites email to friend print save as pdf

Related Stories

First human gets new antibody aimed at hepatitis C virus

Aug 06, 2009

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety ...

New diabetes treatments aim for never-ending honeymoon

Feb 24, 2011

Type 1 diabetes worsens over time – but like most marriages, it starts with a honeymoon. In type 1 diabetes the honeymoon follows diagnosis. The disease is caused by the loss of insulin-secreting beta ...

Many cancer cells found to have an 'eat me' signal

Dec 22, 2010

Researchers at the Stanford University School of Medicine have discovered that many cancer cells carry the seeds of their own destruction — a protein on the cell surface that signals circulating immune cells to engulf ...

Recommended for you

Gate for bacterial toxins found

6 hours ago

Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Freiburg have discovered the receptor responsible ...

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

How kids' brain structures grow as memory develops

Our ability to store memories improves during childhood, associated with structural changes in the hippocampus and its connections with prefrontal and parietal cortices. New research from UC Davis is exploring ...

Ebola virus in Africa outbreak is a new strain

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.